{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:50:09Z","timestamp":1786737009307,"version":"build-2736575974"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Perspect Clin Res"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/picr.picr_177_20","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T03:28:03Z","timestamp":1594006083000},"page":"115","source":"Crossref","is-referenced-by-count":9,"title":["Challenges and opportunities for sponsors in conducting clinical trials during a pandemic"],"prefix":"10.4103","volume":"11","author":[{"given":"Sanish","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-3485.288956-1","unstructured":"Office Circular Issued by CDSCO dated. Regarding Conduct of clinical Trial during Special Situation Due to Outbreak of COVID-19; 30 March, 2020."},{"key":"key-10.4103\/2229-3485.288956-2","unstructured":"FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. Guidance for Industry, Investigators, and Institutional Review Boards; Edition March 2020 updated on 02 June 2020. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents. [Last accessed on 2020 Jun 01]."},{"key":"key-10.4103\/2229-3485.288956-3","unstructured":"MHRA Guidance on Coronavirus (COVID-19). Published 19 March 2020 and updated on 26 May, 2020. Available from: https:\/\/www.gov.uk\/guidance\/managing-clinical-trials-during-coronavirus-covid-19 (Guidance Document) issued by MHRA 2020. [Last accessed on 2020 Jun 01]."},{"key":"key-10.4103\/2229-3485.288956-4","unstructured":"Guidance on the Management of Clinical Trials during the COVID-19 (coronavirus) Pandemic Version 3. Available from: https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-10\/guidanceclinicaltrials_covid19_en.pdf. Guidance document issued by EMA 28April2020. [Last assessed on 2020 Jun 01]."},{"key":"key-10.4103\/2229-3485.288956-5","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1001\/jama.2020.4689","article-title":"Preserving clinical trial integrity during the coronavirus pandemic","author":"McDermott","year":"2020","journal-title":"JAMA"},{"key":"key-10.4103\/2229-3485.288956-6","unstructured":"Indian Society for Clinical Research (ISCR). Available from: https:\/\/www.iscr.org\/[Last assessed on 2020 Jun 01]."},{"key":"key-10.4103\/2229-3485.288956-7","doi-asserted-by":"crossref","unstructured":"Waterhouse DM, Harvey RD, Hurley P, Levit LA, Kim ES, Klepin HD, et al. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey [published online ahead of print, 2020 May 12]. JCO Oncol Pract 2020;OP2000275. doi:10.1200\/OP.20.00275.","DOI":"10.1200\/OP.20.00275"}],"container-title":["Perspectives in Clinical Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:48:53Z","timestamp":1786733333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.PICR_177_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"alternative-id":["288956"],"URL":"https:\/\/doi.org\/10.4103\/picr.picr_177_20","relation":{},"ISSN":["2229-3485"],"issn-type":[{"value":"2229-3485","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}